UGT1A1 and acute lymphoblastic leukemia: 6-mercaptopurine (6-MP), an antimetabolite drug used in treating ALL along with other chemotherapeutic agents that inhibit DNA and RNA synthesis, can decrease the production of the UGT1A1 enzyme in hepatocytes [8].